COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 31-40

  Ballinger, A ^a   Smith, G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cyclooxygenase; Misoprostol; Non steroidal anti inflammatory drugs; Peptic ulceration; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PLACEBO; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; STEROID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PROSTAGLANDIN SYNTHESIS; REVIEW; STOMACH MUCOSA; ULCER HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL NEOPLASMS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTON PUMPS;

EID: 0035002905     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.31     Document Type: Review

References (60)

1. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs
2. Evidence for two antigenically distinct molecular weight variants of prostaglandin H synthase in the rat ovary
3. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog and human gastrointestinal tracts
4. Prostanoids as regulators of gastrointestinal function
5. Gastric mucosal injury by fatty and acetylsalicylic acids
6. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro
7. Human intestinal epithelial cells respond to Cryptosporidium parvum infection with increased prostaglandin H synthase 2 expression and prostaglandin E2 and F2alpha production
8. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease
9. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans
10. Cox-2 inhibitors
11. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta
12. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
13. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
14. Cyclooxygenase 1 and cyclooxygenase 2 selectivity of widely used nonsteroidal anti-inflammatory drugs
15. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
16. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. The double-edged sword
17. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
18. Non-steroidal anti-inflammatory drugs and peptic ulcers
19. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
20. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A meta-analysis
21. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
22. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding
23. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
24. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis. A randomized, double-blind, placebo controlled trial
25. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding
26. Evidence of aspirin use in both upper and lower gastrointestinal perforation
27. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease
28. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
29. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
30. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
31. Non-steroidal anti-inflammatory drug gastropathy
32. How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs? Baillieres Best Pract
33. Non-steroidal anti-inflammatory drugs and benign oesophageal stricture
34. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans
35. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs
36. Clinical, endoscopic and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon
37. Upper gastrointestinal endoscopy in normal asymptomatic volunteers
38. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
39. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis
40. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
41. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
42. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group
43. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats
44. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor and indomethacin in the experimental rat
45. Effects of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer
46. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group
47. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs
48. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy
49. Does eradication of H. pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomised study
50. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention
51. Prevention of peptic ulceration in patients receiving NSAIDs
52. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs
53. Sulindac for polyposis of the colon
54. Aspirin use and risk of fatal cancer
55. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
56. Expression of cyclooxygenase-2 in human gastric carcinoma
57. Altered eicosanoid levels in human colon cancer
58. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
59. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
60. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis